Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas.
Saved in:
| Title: | Single-agent rituximab and ultra-low-dose adaptive radiotherapy for the treatment of indolent B-cell non-Hodgkin lymphomas. |
|---|---|
| Authors: | Lake KE; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Jackson M; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Hull S; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., All S; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Patel AM; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Li X; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Desai NB; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Yilmaz E; Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Wolfe H; Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Zahid MF; Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Li HC; Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Awan F; Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Kozak MM; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Ramakrishnan Geethakumari P; Department of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States., Kumar KA; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2025 Jul 31; Vol. 15, pp. 1617087. Date of Electronic Publication: 2025 Jul 31 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2025.1617087 |
